Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.76

-2.1%

Dec 30 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1808)	2/8/2008 12:44:49 PM
From: Jibacoa	Read Replies (1) of 3722

MGRM has been up 10.23 % & still is up 9.44% on volume of 90,927 already > its ADV. But is finding resistance again at the $1.40 level.<g> bigcharts.marketwatch.com It announced yesterday its 4thQ results, which showed revenues of $13.7M, 34% higher than the $10.2M in 2006. The increase was mainly due to the growth in its Trofile assay, for selecting the HIV patients to be treated with PFE's Selzentry.(Revenue from Trofile in the 4thQ was $2.6 M) The loss was $4.7M vs. $7.6 million in the 3rd Q & $7.0M in 2006. The EL for 2008 is around $0.14 vs. the $0.23 in 2007 & for 2009 a further cut in the loss to $0.10 is expected.<g> MGRM had approximately $30.6M in cash at the end of 2007. Trofile is also available outside of the U.S. where PFE is taking the lead in commercializing it. the end of June and in approximately 40 countries worldwide by the end of the year. MRGM's HERmark also seems to have potential, since less than 50% of metastatic breast Ca. patients selected for treatment with Herceptin tests actually respond & there is concern that IHC and FISH tests may not be adequate, & the HERmark Assay provides more precise measurements of HER2 expression.MRGM expects to have clinical validation of HERmark as a tool to identify the appropriate patients for Herceptin therapy.It is based on the VeraTag technology, which tries to identify resistance pathways not only for Herceptin in breast Ca, but also the drug response and resistance in other cancer types. The stock still needs to get off the DT coming from its April H at $2.60 before it can test the Jan 2004 H at $4.40 Its July 200 H was $26.75 <g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next